Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Padcev (enfortumab vedotin) for the treatment of patients with urothelial carcinoma
- Adcetris (brentuximab vedotin) for the treatment of patients with classical Hodgkin lymphoma
- Mounjaro KwikPen for the treatment of type 2 diabetes in patients treated with at least two hypoglycemic drugs, with defined obesity, and very high cardiovascular risk
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
